Citi Pharma Expands Portfolio with Veterinary Subsidiary

Citi Pharma Limited said Friday that its wholly owned subsidiary, Citi Veterinary Limited, has started trading operations. The company reported to the Pakistan Stock Exchange that Citi Veterinary is initially launching 32 veterinary products, including vaccines, with letters of credit established for eight products to secure supply. For fiscal 2025-26, Citi Veterinary projects turnover of about Rs. 1.5 billion with a gross margin of 13%. The company added that its supply chain partners in China will ensure consistent product availability in Pakistan. Citi Veterinary aims to scale operations to reach Rs. 10 billion in turnover within three years. On the production side, the company said it has submitted its plant layout to the Drug Regulatory Authority of Pakistan, with inspection expected in December 2025. Trial production is targeted for late fiscal 2025-26, with commercial production to begin in fiscal 2026-27. Citi Veterinary also plans to establish Pakistan’s first dedicated veterinary active pharmaceutical ingredient plant in fiscal 2026-27. Once in-house production begins, the company expects its gross profit margin to rise to around 25%.